Safer, One-Time Injection Reduces Inflammation Associated With Common Eye Diseases
This viral vector treats inflammation-associated eye diseases through a safer single injection. Inflammation causes pain and reduced vision in many eye diseases such as diabetic retinopathy, which affects more than 10 million people. Inflammation can serve a useful purpose, helping to remove potentially harmful materials from an injury site. Uveitis, age-related macular degeneration, and diabetic retinopathy are all associated with the excessive production of inflammasome activated cytokines, the proteins that signal for inflammation. Researchers at the University of Florida have developed a viral vector that controls the production of these inflammasome activated cytokines. Available treatments for this inflammation and inflammatory damage are invasive and increase risk of infection or other complications such as glaucoma. This viral vector could be provided in a single injection, restoring vision to patients without the risks of surgery or immune suppression.
ApplicationTherapy for eye diseases including uveitis, age-related macular degeneration, and diabetic retinopathy
- Administered through single injection, improving patient safety and comfort
- Does not induce immune suppression, avoiding infection risks of available treatments